CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis

The HER2-specific monoclonal antibody (mAb), trastuzumab, has been the mainstay of therapy for HER2(+) breast cancer (BC) for approximately 20 years. However, its therapeutic mechanism of action (MOA) remains unclear, with antitumor responses to trastuzumab remaining heterogeneous and metastatic HER...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCI Insight
Main Authors: Tsao, Li-Chung, Crosby, Erika J., Trotter, Timothy N., Agarwal, Pankaj, Hwang, Bin-Jin, Acharya, Chaitanya, Shuptrine, Casey W., Wang, Tao, Wei, Junping, Yang, Xiao, Lei, Gangjun, Liu, Cong-Xiao, Rabiola, Christopher A., Chodosh, Lewis A., Muller, William J., Lyerly, Herbert Kim, Hartman, Zachary C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6975273/
https://ncbi.nlm.nih.gov/pubmed/31689243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.131882
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados